Illexcor is developing a first-in-class oral drug that directly targets the root cause of sickle cell disease. Their lead asset, currently in preclinical development, is designed to bind to Hemoglobin S and effectively block polymerization and sickling, offering the potential for disease-modifying
clinical benefits.Also Read: Zydus Lifesciences gets final USFDA approval to manufacture antifungal shampoo
Dr Sharvil Patel, MD of Zydus Lifesciences, said, “This investment reflects our commitment to patients battling rare and orphan diseases. Recognizing the profound impact of sickle cell disease on patients’ lives, we are pleased to support Illexcor in their efforts to develop a novel therapeutic solution addressing this critical unmet medical need.”Sickle cell disease is a devastating and debilitating genetic condition that affects up to 10 million people worldwide. The disease continues to severely impact quality of life and longevity. Highly efficacious oral drug therapies are urgently needed to manage this condition on a global scale.
Andrew Fleischman, CEO of Illexcor, said, “We are excited to partner with Zynext Ventures to advance our lead drug ILX002 into clinical trials later this year.
Also Read: Zydus Life board approves block acquisition of 85.6% equity of Amplitude Surgical for €256.8 million
We are hopeful that ILX002 will be a transformative treatment not only for SCD patients in the U.S. but also for millions around the globe. Zynext Ventures and Zydus Lifesciences are in a strategic position to help us achieve these goals.”
Shares of Zydus Lifesciences Ltd ended at ₹889.00, down by ₹10.90, or 1.21%, on the BSE.
First Published: Mar 12, 2025 10:44 pm IS
